267 related articles for article (PubMed ID: 31808620)
21. Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines.
Collins G; Mesiano S; DiFeo A
Reprod Sci; 2019 May; 26(5):609-618. PubMed ID: 29848180
[TBL] [Abstract][Full Text] [Related]
22. Expression of type 2 orexin receptor in human endometrium and its epigenetic silencing in endometrial cancer.
Dehan P; Canon C; Trooskens G; Rehli M; Munaut C; Van Criekinge W; Delvenne P
J Clin Endocrinol Metab; 2013 Apr; 98(4):1549-57. PubMed ID: 23482607
[TBL] [Abstract][Full Text] [Related]
23. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract][Full Text] [Related]
24. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
25. UPF1 impacts on mTOR signaling pathway and autophagy in endometrioid endometrial carcinoma.
Zhang M; Chen H; Qin P; Cai T; Li L; Chen R; Liu S; Chen H; Lin W; Chen H; Strickland AL; Xiong H; Jiang Q
Aging (Albany NY); 2021 Sep; 13(17):21202-21215. PubMed ID: 34520393
[TBL] [Abstract][Full Text] [Related]
26. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
27. LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.
Marshall AD; van Geldermalsen M; Otte NJ; Anderson LA; Lum T; Vellozzi MA; Zhang BK; Thoeng A; Wang Q; Rasko JE; Holst J
Int J Cancer; 2016 Dec; 139(11):2529-39. PubMed ID: 27486861
[TBL] [Abstract][Full Text] [Related]
28. Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Zhang SQ; Cai B; Liu L; He YY; Yang YX; Wan XP
Int J Gynecol Cancer; 2009 Nov; 19(8):1377-83. PubMed ID: 20009893
[TBL] [Abstract][Full Text] [Related]
29. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
[TBL] [Abstract][Full Text] [Related]
30. PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma.
Zhang HZ; Li XH; Zhang X; Zhang ZY; Meng YL; Xu SW; Zheng Y; Zhu ZL; Cui DS; Huang LX; Yan BY; Sun XF
Chemotherapy; 2010; 56(4):291-7. PubMed ID: 20714146
[TBL] [Abstract][Full Text] [Related]
31. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
32. Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells.
Yi Z; Jingting C; Yu Z
Int J Gynecol Cancer; 2009 Apr; 19(3):326-33. PubMed ID: 19407554
[TBL] [Abstract][Full Text] [Related]
33. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
34. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
35. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Cantrell LA; Zhou C; Mendivil A; Malloy KM; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2010 Jan; 116(1):92-8. PubMed ID: 19822355
[TBL] [Abstract][Full Text] [Related]
36. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative effect of metformin on the endometrium--a clinical trial.
Tabrizi AD; Melli MS; Foroughi M; Ghojazadeh M; Bidadi S
Asian Pac J Cancer Prev; 2014; 15(23):10067-70. PubMed ID: 25556427
[TBL] [Abstract][Full Text] [Related]
38. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052
[TBL] [Abstract][Full Text] [Related]
39. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
Zou J; Hong L; Luo C; Li Z; Zhu Y; Huang T; Zhang Y; Yuan H; Hu Y; Wen T; Zhuang W; Cai B; Zhang X; Huang J; Cheng J
Cancer Sci; 2016 Dec; 107(12):1806-1817. PubMed ID: 27636742
[TBL] [Abstract][Full Text] [Related]
40. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]